Reapplix
  • About Reapplix
    • About Reapplix
    • About 3C Patch®
    • Executive Management
    • Board of Directors
    • Investors
  • News and press
  • Conferences
  • Contact
Select Page

Reapplix scientific team presented data at The Diabetic Lower Extremity Symposium

Nov 10, 2017

Data were presented in a poster format and was titled: “3C Patch derived autologous immune cells delivers immune responses appropriate for the treatment of Diabetic Foot Ulcers”
← Reapplix presents poster at Diabetic Foot Study Group meeting in Porto Dr. Magnus Löndahl presented Clinical experiences with LeucoPatch and the status of the large RCT at the Innovations in Wound Healing meeting. →

RECENT POSTS

  • PRESS RELEASE: Reapplix Receives Innovative Technology Contract from Vizient for the 3C Patch® Wound Management System 22/05/2023
  • PRESS RELEASE: REAPPLIX RECEIVES CODING AND REIMBURSEMENT DETAILS FOR 3C PATCH® IN THE US – ALL OBSTACLES REMOVED FOR COMMERCIAL EXECUTION 06/10/2021
  • Press Release: Former Urgo Medical Exec Kira Rupprecht Joins Reapplix as Chief Executive Officer 03/05/2021
  • PRESS RELEASE: A FINAL MEDICARE NATIONAL COVERAGE DETERMINATION HAS BEEN PUBLISHED ENABLING SUSTAINABLE US REIMBURSEMENT FOR REAPPLIX’s 3C PATCH® 21/04/2021
  • PRESS RELEASE: REAPPLIX ANNOUNCES APPOINTMENT OF RICHARD TWOMEY TO BOARD OF DIRECTORS 20/10/2020

REAPPLIX INC / US

+1 866 327 2824
Mail to Reapplix US

VISIT OUR PRODUCT SITE 3CPATCH.COM

REAPPLIX A/S HQ / EUROPE

+45 88 16 80 66
Mail to Reapplix Europe

© 2023 Reapplix A/S. All Rights Reserved. 3C Patch® and 3C Patch System® are registered trademarks of Reapplix A/S. For full safety information, please reference the 3C Patch® Instructions for Use. Read our Privacy Policy and Cookie Policy.